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Glucocorticoids (GCs) are common components of many chemotherapeutic regimens for lymphoid malignancies including
acute lymphoblastic leukemia (ALL). The BCL-2 family has an essential role in regulating GC-induced cell death. Here we show
that downregulation of antiapoptotic BCL-2 family proteins, especially MCL-1, enhances GC-induced cell death. Thus we target
MCL-1 by using GX15-070 (obatoclax) in ALL cells. Treatment with GX15-070 in both dexamethasone (Dex)-sensitive
and -resistant ALL cells shows effective growth inhibition and cell death. GX15-070 induces caspase-3 cleavage and increases
the Annexin V-positive population, which is indicative of apoptosis. Before the onset of apoptosis, GX15-070 induces LC3
conversion as well as p62 degradation, both of which are autophagic cell death markers. A pro-apoptotic molecule BAK is
released from the BAK/MCL-1 complex following GX15-070 treatment. Consistently, downregulation of BAK reduces caspase-3
cleavage and cell death, but does not alter LC3 conversion. In contrast, downregulation of ATG5, an autophagy regulator,
decreases LC3 conversion and cell death, but does not alter caspase-3 cleavage, suggesting that apoptosis and autophagy
induced by GX15-070 are independently regulated. Downregulation of Beclin-1, which is capable of crosstalk between apoptosis
and autophagy, affects GX15-070-induced cell death through apoptosis but not autophagy. Taken together, GX15-070 treatment
in ALL could be an alternative regimen to overcome glucocorticoid resistance by inducing BAK-dependent apoptosis and
ATG5-dependent autophagy.
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Glucocorticoids (GCs) are common components in many
chemotherapeutic protocols for lymphoid/myeloid malignan-
cies, including acute lymphoblastic leukemia (ALL). However,
patients often develop resistance to GCs on relapse.
Resistance to GCs in ALL can be associated with defects in
apoptosis machinery and not in the GC receptor.
1–4 Thus,
targeting downstream molecules may lead to the develop-
ment of new therapeutic strategies. GC-induced apoptosis is
through the intrinsic mitochondria-dependent pathway.
5–7
The BCL-2 family proteins are central regulatory proteins in
this pathway.
8,9 The BCL-2 family is subdivided into three
main groups based on regions of BCL-2 homology (BH) and
function: multi-domain antiapoptotic (e.g., BCL-2, MCL-1,
BCL-XL), multi-domain pro-apoptotic (e.g., BAX, BAK),
and BH3-only pro-apoptotic (e.g., BAD, BID, BIM, PUMA).
BH3-only proteins cause cytochrome c release by activating
BAX and/or BAK, while the antiapoptotic BCL-2 family
of proteins prevents this process.
10,11 Targeting the BCL-2
family proteins might be a strategy to overcome GC
resistance. We and others have shown that BIM, a
pro-apoptoticBH3-onlyprotein,isupregulatedbydexametha-
sone (Dex) treatment in ALL cells and has an essential role in
Dex-induced apoptosis.
12 We then have demonstrated that
co-treatment with Dex (for BIM upregulation) and MEK/ERK
inhibitors (for BIM dephosphorylation/activation) promotes
apoptosis in a variety of ALL cells.
9 GC resistance is also
derived from aberrant changes in the regulation of anti-
apoptotic proteins. Recent studies have shown that increased
expression of MCL-1 is associated with GC resistance.
13–15
MCL-1 is distinct among other antiapoptotic proteins, with
its short protein turnover being regulated by the 26S
proteasome.
16 Thus, downregulation or inactivation of
MCL-1 could be attractive to resensitize the chemotherapeutic
response in ALL.
Recently, small molecules that directly interact with
antiapoptotic BCL-2 proteins have been developed.
17,18
These agents interact with antiapoptotic BCL-2 family
proteins at their BH3-binding grooves and mimic the action
of BH3-only proteins. Among the small-molecule antagonists
of antiapoptoticBCL-2 familyproteins, GX15-070(obatoclax),
which is an indole bipyrrole compound, exhibits potency
against MCL-1.
19,20 Although GX15-070 is currently used in
developingsingle-agenttherapyorincombinationinphaseI/II
clinical trials directed at leukemia,
21,22 the molecular mechan-
isms of cell death induced by GX15-070 are not entirely clear.
Some recent reports suggest the induction of autophagy and
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A major form of autophagy is macroautophagy, in which
parts of the cytoplasm and intracellular organelles are
sequestered within a double autophagic membrane. Auto-
phagosome formation is dependent on the interaction and
activity of ATG proteins. Lipid–protein and protein–protein
conjugations occur during autophagosome formation. One of
theimportantconjugationsisbetweencleavedATG8/LC3and
phosphatidylethanolamine. This conjugation is an event to
form an autophagosome structure and can be used as an
autophagy marker. In the second conjugation event, ATG12
covalently binds to ATG5. ATG5 then associates with ATG16,
which is required for autophagosome elongation. Beclin-1/
ATG6hasaroleintheinitiationofautophagy,byitsinteraction
with class III phosphatidylinositol-3 kinase.
29 Furthermore,
Beclin-1 has been reported as a BH3-only protein interacting
with BCL-2 and BCL-XL, indicating that it is capable of
crosstalk between autophagy and apoptosis.
30
In this study, we show that GX15-070 induces cell death
through BAK-dependent apoptosis and ATG5-dependent
autophagy not only in Dex-sensitive, but also in Dex-resistant
ALL cells. Thus, GX15-070 treatment in ALL could be an
alternative regimen to overcome GC resistance.
Results
Downregulation of MCL-1 enhances Dex-induced
lethality in ALL cells. We and others have previously
shown that BIM, a pro-apoptotic BH3-only protein, has an
essential role in executing Dex-induced cell death in ALL
cells. BIM is capable of interacting with all antiapoptotic
BCL-2 family proteins (i.e., BCL-2, BCL-XL, MCL-1, BCL-w,
and A1). To examine whether these antiapoptotic molecules
have a speciﬁc role in Dex-induced apoptosis, we introduced
shRNA for BCL-2 or MCL-1 into CCRF-CEM (CEM) T-ALL
cells, and determined the effect on Dex-induced cell death.
Downregulation of MCL-1 strongly enhanced apoptosis
induced by Dex compared with the downregulation of
BCL-2 (Figure 1). Downregulation of BIM showed signiﬁ-
cant reduction of Dex-induced apoptosis, as previously
demonstrated.
9 The results presented here and those of a
previous publication
31 suggest that inactivation of MCL-1 can
sensitize Dex-induced cell death in ALL cells.
GX15-070 kills both Dex-sensitive and -resistant ALL
cells. GX15-070 is a small compound that targets all
antiapoptotic BCL-2 family proteins. The results in Figure 1
prompted us to examine whether GX15-070 induces cell
death in ALL cells. We ﬁrst determined the dose response of
GX15-070 as a single agent for the induction of cell death
and found that the concentration of 100nM showed effec-
tive cell death activity in CEM cells (data not shown).
Co-treatment of Dex-sensitive CEM cells with 100nM Dex
and 100nM GX15-070 showed an additive killing effect as
compared with each treatment alone (Figure 2a and b).
We then treated Dex-resistant Molt-4, Reh, HSB-2, and Jurkat
ALL cells with 100nM of GX15-070. GX15-070 inhibited
cell proliferation and induced cell death (Figure 2a and b).
In contrast to CEM cells, no additive effect was observed by
co-treatment with Dex and GX15-070 in these cells. Thus, the
results strongly indicate that GX15-070 as a single agent is
capable of overcoming Dex resistance in ALL cells.
GX15-070 induces apoptosis and autophagy. Increased
population of Annexin V-positive cells (Figure 2b) indicates
that cell death is induced by GX15-070 treatment. We further
conﬁrmed GX15-070-induced apoptosis by detection of
caspase-3 and PARP cleavages in CEM cells (Figure 3a).
To examine whether GX15-070-induced cell death is
caspase-dependent, we added a pan-caspase inhibitor
Z-VAD-FMK (Z-VAD) in GX15-070-treated CEM cells.
Although caspase-3 and PARP cleavages were inhibited by
Z-VAD (Figure 3a), total cell death induced by GX15-070 was
not affected (Figure 3b). We thus examined whether other
cell death pathways such as autophagy or caspase-
independent cell death were induced. The conversion from
LC3-I to -II, which is indicative of autophagy, was observed
with GX15-070 treatment in CEM, HSB-2, and Jurkat cells
(Figure 3a and c). However, we could not detect LC3
conversion with Dex treatment in these cells, suggesting that
autophagy induction is speciﬁc to GX15-070 treatment.
Furthermore, following GX15-070 treatment, RFP-LC3
transfected into CEM cells displayed punctated particles
that show autophagosome formation and conversion of LC3-I
to -II (Figure 3d). AIF release in cytosol, indicative of
caspase-independent cell death, was also detected with
GX15-070 treatment (Figure 3e). Interestingly, by the
addition of Z-VAD, LC3 conversion was not altered
(Figure 3a) and AIF release was increased (Figure 3e),
suggesting that blocking GX15-070-induced caspase-
dependent apoptosis by Z-VAD forced the cells to commit
to caspase-independent apoptosis and autophagy.
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Figure 1 Downregulation of MCL-1 enhances dexamethasone-induced
lethality. Left panel: CEM cells were infected with lentiviruses expressing shRNAs
for non-targeting control, BIM, MCL-1, or BCL-2. Puromycin-resistant cells were
pooled after each infection. Equal amounts of total cell extracts were subjected to
western blotting with the indicated antibodies. Right panel: Cells were treated with
100nM Dex for 48h. The percentage of apoptotic cells was determined by Annexin
V-propidium iodide (PI) staining followed by FACS analysis. Values represent the
mean±S.D. of three independent experiments
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Figure 2 GX15-070 has lethality effect in both Dex-sensitive and -resistant ALL cells. (a) ALL cell lines including CEM, Molt-4, Jurkat, Reh, or HSB-2 were treated with
100nM GX15-070 (GX) for indicated times and growth rate was determined by WST-1 colorimetric assay. Error bars represent the standard error of three independent
experiments. (b) Cells were treated with 100nM Dex and/or 100nM GX15-070 for 48h. The percentage of cell death was determined by Annexin V-PI staining followed by
FACS analysis. Values represent the mean±S.D. of three independent experiments
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Cell Death and DiseaseWe next performed a time-course study to examine
when autophagy and apoptosis started and proceeded by
GX15-070 treatment. Autophagy judged by LC3 conversion
was detected within 6h after the treatment, while apoptosis
judged by caspase-3 cleavage was detected at the later time
points (Figure 4a and b). The most dramatic difference
between the onset of autophagy and apoptosis was observed
in Molt-4 cells. We also detected a massive decrease in
p62 expression, which is another marker for autophagy
(Figure 4b).
29 Taken together, GX15-070 induces multiple
cell death pathways such as caspase-dependent, -indepen-
dent apoptosis, and autophagy.
GX15-070 induces BAK-dependent apoptosis in ALL
cells. We further investigated the potential molecular
mechanisms of how GX15-070 induces multiple cell death
pathways. As BAK interacts with MCL-1 under normal condition
and is released to be activated upon cell death stimuli,
32 we
examined the interaction of BAK with MCL-1 after GX15-070
treatment. We detected dissociation of BAK/MCL-1 at 5h after
treatment with GX15-070 (Figure 5a). Following the
dissociation, we noticed that expression of MCL-1 was
decreased at 16–24h, while the expression levels of BAX,
BAK, BIM, BCL-2, and BCL-XL remained constant (Figure 5b).
Cleaved MCL-1 was increased in accordance with decrease of
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Figure 3 Apoptosis and autophagy are induced by GX15-070 treatment. (a) CEM cells were treated with 100nM GX15-070±50mM Z-VAD for 32h. Z-VAD was added
30min before GX15-070 treatment. Cleavage of PARP or caspase-3 and LC3 conversion were detected by western blot analyses. (b) CEM cells were treated with 100nM
GX15-070 in the presence or absence of 50mM Z-VAD for 48h. The percentage of cell death was determined by Annexin V-PI staining followed by FACS analysis. Values
representthe mean±S.D. of three independentexperiments. (c) Dex-sensitive CEM or -resistantHSB-2and Jurkat cellswere treatedwith 100nMDex or 100nM GX15-070
for24h,andLC3conversionandcaspase-3cleavageweredetectedbywesternblotanalyses.(d)CEMcellswerestablytransfectedwithRFP-LC3,andG418-resistantclone
cellswerethentreatedwith100nMGX15-070for24h.PunctatedRFP-LC3wasvisualizedunderaﬂuorescentmicroscope.Westernblotanalysisconﬁrmedtheconversionof
RFP-LC3. These pictures are representative of three independent experiments. Magniﬁcation is 40. Bottom pictures are enlarged single-cell images. (e) CEM cells were
treated with 100nM GX15-070±50mM Z-VAD for 24h and release of cytochrome c or AIF in cytosol fraction was determined by western blot analyses
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Cell Death and Diseasefull-length MCL-1 (Figure 5c). Addition of MG-132, a
proteasome inhibitor, restored the level of MCL-1 from GX15-
070-mediated degradation (Figure 5d), suggesting that the
degradation of MCL-1 is proteasome-dependent.
Downregulation of BAK, but not BAX, signiﬁcantly inhi-
bited apoptosis judged by Annexin V-positive population
(Figure 6a) and caspase-3 cleavage (Figure 6b), suggesting
that GX15-070-induced apoptosis is BAK-dependent. Taken
together, these results indicate that GX15-070-induced
apoptosis is initiated by the inhibition of MCL-1 binding to
BAK, and then the amount of free BAK increases by MCL-1
degradation, which may amplify the apoptotic effect of BAK.
GX15-070-induced autophagy is ATG5-dependent
in ALL cells
We next investigated the molecular mechanisms of
GX15-070-induced autophagy. ATG5 is known to function in
autophagosome formation and completion. We could
not establish the CEM cells in which ATG5 was down-
regulated, as knocking down of the ATG5 gene itself killed the
cells(datanotshown).DownregulationofATG5inMolt-4cells
reduced LC3 conversion as well as total cell death induced by
GX15-070 treatment (Figure 7a and b). Thus, GX15-070-
inducedautophagyisATG5-dependentandcontributestocell
death.
Beclin-1 is a key regulator of classical autophagy. Down-
regulation of Beclin-1 reduced GX15-070-induced cell death
in both CEM and Molt-4 cells (Figure 8a). However, LC3
conversionwasnotaltered(Figure8b).Theactivationofclass
III phosphoinositide 3-kinase (PI3K III) is essential to induce
autophagy through Beclin-1.
33,34 We thus examined whether
inhibition of PI3K III by LY294002 or 3-MA could inhibit
autophagy. Neither LY294002 nor 3-MA affected GX15-070-
mediated LC3 conversion (Supplementary Figure S1a and b).
These data suggest that GX15-070-induced autophagy is
Beclin-1-independent.
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Cell Death and DiseaseApoptosis and autophagy induced by GX15-070
treatment are independently regulated. We next
addressed whether there is any crosstalk between
apoptosis and autophagy induced by GX15-070 treatment.
Our results show that when apoptosis was reduced by
downregulation of BAK, LC3 conversion was not affected
(Figure 6a and b). In contrast, caspase-3 cleavage was not
altered by downregulation of ATG5 when autophagy was
reduced (Figure 7b), suggesting that apoptosis and
autophagy are independently regulated by GX15-070
treatment.
Beclin-1, an autophagy regulator, is also known to
physically interact with BCL-2 and BCL-XL as a BH3-only
protein, suggesting that Beclin-1 could mediate crosstalk
between autophagy and apoptosis pathways. Although
GX15-070-induced autophagy was not affected by down-
regulation of Beclin-1 in CEM and Molt-4 cells, the amount of
cell death was decreased (Figure 8a and b). We thus
examined the role of Beclin-1 in the apoptosis pathway. In
thecaseofCEMcells,downregulationofBeclin-1reducedthe
amount of caspase-3 cleavage induced by GX15-070,
suggesting that caspase-dependent apoptosis is partly
regulated by Beclin-1 (Figure 8b). We did not observe any
changes in the amount of AIF released after Beclin-1
knockdown in CEM cells (data not shown). On the contrary,
Beclin-1 downregulation did not alter GX15-070-induced
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Cell Death and Diseasecaspase-3 cleavage in Molt-4 cells while AIF release was
decreased, suggesting that caspase-independent apop-
tosis is also regulated by Beclin-1 expression (Figure 8b).
To further examine the role of Beclin-1 in crosstalk between
autophagy and apoptosis, we determined the interactions of
Beclin-1 with BCL-2, Beclin-1 with BCL-XL, and Beclin-1 with
MCL-1 following GX15-070 treatment. Co-immunoprecipita-
tionwithanti-Beclin-1followedbywesternblotwithanti-BCL-2
or anti-BCL-XL revealed that the interactions were not altered
by GX15-070 in both CEM and Molt-4 cells (Figure 8c).
However, we could not detect any interaction of Beclin-1 with
MCL-1 in both cell lines (data not shown). Reciprocal
co-immunoprecipitation with anti-BCL-2 followed by western
blot with anti-Beclin-1 conﬁrmed the interaction of Beclin-1
with BCL-2 without any alteration by GX15-070 treatment
(Figure 8d). Taken together, these results suggest that Beclin-1
does not have a role in inducing autophagy by GX15-070, but
has a substantial role in GX15-070-induced apoptosis.
Discussion
GCs have been used in chemotherapy for leukemia,
lymphoma, and myeloma for decades. Although they are
effective in the initial stages, resistance on relapse often
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Figure 8 Beclin-1 contributes to GX15-070-induced apoptosis but not to autophagy. (a) CEM or Molt-4 cells were infected with lentiviruses expressing shRNAs for either
non-targeting control or Beclin-1 (Bec). Puromycin-resistant cells were pooled after each infection. Downregulation of Beclin-1 expression was monitored by western blotting
(in sets). Cells were treated with 100nM GX15-070 for 48h and the percentage of cell death was determined by Annexin V-PI staining followed by FACS analysis. Values
representthemean±S.D.ofthreeindependentexperiments.(b)Cellsweretreatedwith100nMGX15-070fortheindicatedtimes,andLC3conversion,caspase-3cleavage,
and AIF release were assessed by western blot analyses. (c) CEM or Molt-4 cells were treated with 100nM GX15-070 for 24h. Total cell extracts were subjected to
immunoprecipitation with anti-Beclin-1. Western blotting was performed on precipitated samples and on lysates collected before immunoprecipitation with Beclin-1, BCL-2,
or BCL-XL antibodies. (d) Reciprocal immunoprecipitation was performed with anti-BCL-2. Western blotting was conducted on precipitated samples and on lysates collected
before immunoprecipitation with BCL-2 or Beclin-1 antibodies
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Cell Death and Diseaseemerges.Themolecularmechanismsofsensitivity/resistance
to this agent are still not fully understood. In this study, we
propose a possible strategy to overcome GC resistance in
ALL by targeting downstream molecules of the GC receptor,
such as the BCL-2 family proteins. We hypothesized that
targeting antiapoptotic MCL-1 might be effective among the
BCL-2 family proteins, as (1) we recognized that treatment
with Dex in CEM or Molt-4 cells slightly induces MCL-1
9 and
that the expression level of MCL-1 is higher in Dex-resistant
ALL cells than in Dex-sensitive cells (Supplementary Figure
S2); (2) recent studies have demonstrated that increased
expressionofMCL-1isassociatedwithGCresistance.
13–15In
support of our hypothesis, downregulation of MCL-1 by
shRNA enhanced Dex-induced cell death (Figure 1). We then
pharmacologically inactivated MCL-1 function by GX15-070,
a BH3 mimetic small molecule that targets antiapoptotic
BCL-2 family proteins including BCL-2, BCL-XL, and MCL-1.
Treatment with GX15-070 induced caspase-3 cleavage and
increased the Annexin V-positive population, which is
indicative of apoptosis. It has been shown that GX15-070
binds to MCL-1 and inhibits the binding with BAK,
19 which
leads to apoptosis. Consistent with the previous ﬁndings,
dissociation of BAK/MCL-1 complex was detected 5h after
GX15-070treatment.Wealsoobserveddramaticdegradation
of MCL-1 at later time points in a proteasome-dependent
manner. These results suggest that BAK activation is
initiated by the release from MCL-1 and probably is ampliﬁed
by MCL-1 degradation. Downregulation of BAK reduced
caspase-3 cleavage and cell death, but did not alter LC3
conversion, indicating that apoptosis but not autophagy is
regulated by BAK.
Before the onset of apoptosis and as early as 6h after the
treatment, GX15-070 induced LC3 conversion as well as p62
degradation, which is indicative of autophagy. Downregula-
tion of ATG5 decreased LC3 conversion and cell death, but
did not alter caspase-3 cleavage. These data suggest that
GX15-070-induced autophagy contributes to cell death but
is not a pre-requisite for commitment to apoptosis. Thus,
ATG5-dependent autophagy and BAK-dependent apoptosis
are independently regulated by GX15-070 treatment. Further-
more, our data suggest that GX15-070-induced autophagy is
executed by the Beclin-1-independent pathway. Downregula-
tion of Beclin-1 did not alter LC3 conversion induced by
GX15-070 treatment (Figure 8b). We can come to the same
conclusion by using LY294002 and 3-MA, inhibitors of PI3K
that are required for autophagy induction through Beclin-1.
Neither LY29002 nor 3-MA affected GX15-070-mediated LC3
conversion (Supplementary Figure S1). Although GX15-070-
induced autophagy was not affected by downregulation of
Beclin-1, the amount of cell death decreased. This reduction
of cell death is mediated through apoptosis, as caspase-3
cleavage or AIF release was decreased by downregulation of
Beclin-1. It has been recently shown that after initiating
apoptosis,Beclin-1iscleavedbycaspasesandtheN-terminal
fragment of Beclin-1 can inhibit autophagy while the
C-terminal fragment can amplify mitochondrial-mediated
apoptosis,
35 suggesting that Beclin-1 has dual function as a
regulator of autophagy and apoptosis. In contrast to this
ﬁnding, the level of full-length Beclin-1 was constant following
GX15-070 treatment, even though caspase-3 was already
active (data not shown). Of note, a recent report described
that autophagy is induced after Dex treatment in Dex-
sensitive ALL cells.
36 However, we could not detect LC3
conversion in CEM cells after Dex treatment when caspase-3
cleavage was clearly observed (Figure 3c). Furthermore, we
showed before that the amount of Dex-induced cell death
was not altered by co-treatment with LY294002,
12 and that
co-treatment with Dex and GX15-070 showed an additive effect
compared with each treatment alone (Figure 2b). Therefore,
GX15-070-induced cell death pathways are distinct and
independent of the Dex-induced cell death pathway.
Recently, Bonapace et al.
28 demonstrated that GX15-070
re-sensitizes GC-resistant ALL cells. Our results demon-
strate that single treatment with a low dose of GX15-070
(i.e., 100nM) sufﬁciently induces growth inhibition and
cell death by inducing BAK-dependent apoptosis and
ATG5-dependent autophagy. The authors observed dissocia-
tion of the Beclin-1/MCL-1 complex with GX15-070 treatment.
In contrast, we could not detect the Beclin-1/MCL-1 complex
in CEM, Molt-4 and Jurkat cells (data not shown), with the
same conditions under which we clearly observed Beclin-1/
BCL-2 and Beclin-1/BCL-XL interaction (Figure 8c and d),
probably because of the amount of existing complex in the
cells. A previous report also showed that the interaction of
MCL-1 and Beclin-1 is not as strong as that between Beclin-1
and BCL-2 and between Beclin-1 and BCL-XL.
37 Thus, further
investigation is required to clarify the mechanism required to
initiate GX15-070-induced autophagy.
Enhanced expression levels of antiapoptotic BCL-2 family
protein have been observed in several types of tumors.
Targeting these proteins is therefore an attractive strategy for
restoring the apoptosis process in tumor cells. Among the
small-molecule BCL-2 inhibitors, ABT-737 and its analog
ABT-263 are the leading compounds that are currently in
clinical development. However, these molecules have an
afﬁnity only for BCL-2 and BCL-XL, but not for MCL-1. Thus,
ABT-737 cannot be effective as a single-agent therapeutic
for ALL when MCL-1 is overexpressed.
17,38 In contrast,
GX15-070 can overcome the resistance conferred by high
levels of MCL-1. Our results suggest that GX15-070 could
be useful as a single-agent therapeutic against ALL and
that the activity/expression of antiapoptotic proteins could
be a biomarker to determine the treatment strategy for
ALL patients.
Materials and methods
Cell lines and culture. CCRF-CEM, Molt-4, HSB-2, Reh, and Jurkat cells
were purchased from the American Tissue Culture Collection (Manassas, VA,
USA). Cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated
fetalbovineserum,1mMsodiumpyruvate,streptomycin,andpenicillinGat371Cin
a humidiﬁed, 5% CO2 incubator.
Chemicals and antibodies. Dex was purchased from Sigma (St Louis, MO,
USA). GX15-070 was provided from Gemin X (Montreal, Quebec, Canada).
MG-132 was purchased from Calbiochem (San Diego, CA, USA). The antibodies
used for western blot and immunoprecipitation were as follows: BAX (N-20),
a-tubulin,b-tubulinandAIFfromSantaCruzBiotechnology(SantaCruz,CA,USA);
BAK from Upstate/Millipore (Billerica, MA, USA); BCL-2 from Sigma; MCL-1 from
Assay Designs (Ann Arbor, MI, USA); BIM, BCL-XL, Beclin-1, ATG5 and caspase-3
from Cell Signaling Technology (Beverly, MA, USA); cytochrome c and p62 from
BD-Pharmingen (San Diego, CA, USA); Beclin-1 and LC3 from Novus Biologicals
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Cell Death and Disease(Littleton, CO, USA); PARPfrom Oncogene(Darmstadt, Germany);WST-1 reagent
from Roche (Mannheim, Germany); and Z-VAD-FMK from ALEXIS Biochemicals
(Lausen, Switzerland).
Lentivirus infection and plasmid transfection. The lentiviral short-
hairpin RNA (shRNA)-expressing constructs were purchased from Open
Biosystems (Huntsville, AL, USA). The constructs were transfected into 293T
packaging cells along with the packaging plasmids, and the lentivirus-containing
supernatants were used to transduce ALL cells. The RFP-LC3 construct was kindly
provided by Dr. David Gewirtz (VCU). Transfection was performed by
electroporation using a Bio-Rad electroporator (Hercules, CA, USA). The cells
were suspended in RPMI 1640 (410
6/400ml) with 10mg of DNA and
electroporated in 0.4-cm cuvettes at 300V and 500mF. Puromycin (2mg/ml for
shRNAs)or G418(800mg/mlfor RFP-LC3)selectionto establishstablecells began
24h after virus infection or electroporation.
Quantitative RT-PCR. Total RNA was extracted by Trizol (Invitrogen,
Carlsbad, CA, USA) from Molt-4 cells infected with shATG5-containing lentivirus.
In all, 1mg of RNA was reverse-transcribed by using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s
instructions. Using Taqman Gene Expression Assay probe/primer Hs00169468
(Applied Biosystems, Foster City, CA, USA), cDNAs were ampliﬁed in a
ﬂuorescence thermocycler (Applied Biosystems 7500HT Fast Real-time PCR
system) and were analyzed based on the expression level of GADPH with SDS2.2
software.
Immunoprecipitation and western blot analyses. Whole-cell lysates
were prepared with CHAPS lysis buffer (20mM Tris (pH 7.4), 137mM NaCl, 1mM
dithiothreitol (DTT), 1% CHAPS (3-((3-cholamidopropyl)dimethylammonio)-1-
propanesulfonate), 20mM NaF, 10mM b-glycerophosphate, and a protease
inhibitor cocktail (Sigma)). For immunoprecipitation, equal amounts of protein were
incubated with the appropriate antibody for 3h on ice. Then antibody complexes
were captured with protein A/G beads (Pierce, Rockford, IL, USA), at 41C for 1h
with rotation. After washing three times with the same lysis buffer, the beads were
re-suspendedinthesamplebufferandthesampleswereseparatedbySDS-PAGE.
For western blot analyses, equal amounts of proteins were loaded on SDS-PAGE,
transferred to a nitrocellulose membrane and analyzed by immunoblotting.
Cell viability assay. Cell proliferation was measured by WST-1 assay. 10
4
CEM,RehorHSB-2and510
3JurkatorMolt-4cellswereculturedin100mlRPMI
and treated with 100nM GX15-070 for 1–4 days. WST-1 (5ml) was added to
samples and they were incubated for 3h at 371C and in 5% CO2. Absorbance of
triplicate samples at 450nm was measured by a multilabel reader (PerkinElmer,
Shelton, CT, USA).
Cell death was quantiﬁed by Annexin V-FITC or -APC (BD Pharmingen) and
propidiumiodide(Sigma)stainingaccordingtothemanufacturer’sprotocol,followed
by ﬂow-cytometric analysis using FACScan (BD Biosciences).
Subcellular fractionation. Two million cells were washed in PBS and lysed
by incubating for 30s at room temperature in digitonin lysis buffer (75mM NaCl,
8mMNa 2HPO4, 1mM NaH2PO4, 1mM EDTA, and 350mg/ml digitonin). Lysates
were centrifuged (12000g) for 1min, and the supernatant (cytosolic fraction)
was collected. Pellets (membrane fractions) were washed once in cold PBS and
lysed in CHAPS lysis buffer. The cytosolicand membrane samples were quantiﬁed,
separated by SDS-PAGE, and subjected to western blot analysis.
Fluorescent microscopy. CEM cells stably expressing RFP-LC3 were
treated with 100nM GX15-070 for 24h. Cells were then analyzed using Olympus
1X70 microscope.
Statistical analysis. Values represent the means±S.D. for three separate
experiments. The signiﬁcance of differences between experimental variables was
determined using the Student’s t-test. Values were considered statistically
signiﬁcant at Po0.05.
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